A5073469490- Retinopathy of Prematurity Studies
- Neonatal Respiratory Health Research
- Neonatal Health and Biochemistry
- Neonatal and fetal brain pathology
- Ophthalmology and Visual Impairment Studies
- Ophthalmology and Eye Disorders
- Intraocular Surgery and Lenses
- Visual perception and processing mechanisms
- Glaucoma and retinal disorders
- Retinal Diseases and Treatments
- Retinal Development and Disorders
- Vestibular and auditory disorders
- Prenatal Substance Exposure Effects
- Ophthalmology and Visual Health Research
- Tactile and Sensory Interactions
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Ocular Diseases and Behçet’s Syndrome
- Cerebral Venous Sinus Thrombosis
- Traumatic Ocular and Foreign Body Injuries
- Mitochondrial Function and Pathology
- Anesthesia and Neurotoxicity Research
- Corneal surgery and disorders
- Preterm Birth and Chorioamnionitis
- Child Abuse and Related Trauma
Smith-Kettlewell Eye Research Institute
2015-2025
California Pacific Medical Center
2009-2025
U.S. National Science Foundation
2018
Clarity Water Treatment Systems (Norway)
2018
University of California, San Francisco
1989-2013
Royal Children's Hospital
2013
The Royal Victorian Eye & Ear Hospital
2013
National Institute on Population Medical Genetics
2010
Columbia University
2008
Millard Fillmore Suburban Hospital
2004-2007
Objectives. To estimate the incidence of retinopathy prematurity (ROP) in Early Treatment for Retinopathy Prematurity (ETROP) Study and compare these results with those reported Cryotherapy (CRYO-ROP) Study. Methods. The ETROP Study, as part its protocol, screened 6998 infants at 26 centers throughout United States. Serial eye examinations were conducted born weighing <1251 g, making it possible to frequency ROP different birth weight gestational age categories. was categorized...
<h3>BACKGROUND/AIMS</h3> To evaluate prevalence, aetiology, prognosis, and associated neurological ophthalmological problems in children with cortical visual impairment (CVI). <h3>METHODS</h3> The records of 7200 outpatients seen the paediatric ophthalmology practice over past 15 years were reviewed order to compile data concerning CVI. In addition, authors devised applied a system for grading recovery assess prognosis. <h3>RESULTS</h3> CVI occurred 2.4% all patients examined. four most...
<h3>Objective</h3>To compare grating (resolution) visual acuity at 6 years of age in eyes that received early treatment (ET) for high-risk prethreshold retinopathy prematurity (ROP) with underwent conventional management (CM).<h3>Methods</h3>In a randomized clinical trial, infants bilateral, ROP (n = 317) had one eye undergo ET and the other CM, only if progressed to threshold severity. For asymmetric cases 84), was or CM.<h3>Main Outcome Measure</h3>Grating measured by masked testers using...
<h3>Objective</h3>To describe the structural and visual outcomes at age 6 years of retinal detachment (RD) from retinopathy prematurity (ROP) in Early Treatment for Retinopathy Prematurity (ETROP) study.<h3>Methods</h3>Prospective multicenter nonrandomized series infants with high-risk prethreshold ROP who developed an RD by months corrected treated observation or vitreoretinal surgery.<h3>Results</h3>Of 401 patients, 63 (89 eyes) experienced RD. Follow-up was available 70 eyes (79%) 49...
Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity. A much lower dose may be effective while reducing risk.To find a intravitreous that was than previously for severe ROP, in this study, and could tested future larger studies.Between May 2015 September 2016, 61 premature infants with ROP or both eyes were enrolled masked, multicenter, phase de-escalation study. One eye 10 14...
To validate a vascular severity score as an appropriate output for artificial intelligence (AI) Software Medical Device (SaMD) retinopathy of prematurity (ROP) through comparison with ordinal disease labels stage and plus assigned by the International Classification Retinopathy Prematurity, Third Edition (ICROP3), committee.Validation study AI-based ROP score.A total 34 experts from ICROP3 committee.Two separate datasets 30 fundus photographs each (0-5) (plus, preplus, neither) were labeled...
To determine if visuocortical development in premature infants with high bilirubin levels is more adversely affected than that full-term infants. 57 preterm were managed using institutional guidelines for hyperbilirubinemia. At 12-months corrected age, Vernier acuity, contrast sensitivity, and grating acuity measured the sweep visual evoked potential (sVEP) correlated to total serum/plasma (TSB) first week of life. As TSB increased, worsened <34 weeks' gestation compared those >34 <37 (p <...
To determine whether earlier treatment of high-risk, prethreshold retinopathy prematurity (ROP) improves retinal structural outcome at 2 years age.Infants with bilateral high-risk ROP had one eye randomly assigned to peripheral ablation. The fellow was managed conventionally, and either treated threshold or observed if never reached. In patients asymmetrical disease, the randomised conventional management. At age, children were examined comprehensively by certified ophthalmologists outcomes...
Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk neurodevelopmental delay. A much lower dose may be effective for ROP while reducing risk. Previously, after testing doses 0.25 0.031 mg, as low were found in small cohorts infants.To find lowest intravitreous severe ROP.Between April 2017 and May 2019, 59 premature infants with or both eyes enrolled a masked,...
Preliminary Results of Treatment Eyes With High-Risk Prethreshold Retinopathy Prematurity in the Early for Randomized Trial